2026-10-27 13:29:43 UTC#521724newconfirmednews
Guggenheim maintains Buy rating on ArriVent BioPharma, sets $30 price target citing ARR-217 clinical progress
tradingviewimportance 0.40trust 0.60Guggenheim Securities, LLC +0.40ArriVent BioPharma, Inc. +0.50ARR-217 +0.50